Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 浙江新光药业股份有限公司主要从事中成药的研发、生产和销售。公司主要产品以治疗心脑血管疾病、外伤科疾病和保健滋补为主，主要产品为黄芪生脉饮、伸筋丹胶囊、西洋参口服液等。公司是国家级高新技术企业、浙江省创新型示范企业、浙江省“五个一批”重点骨干企业，是一家集研究、生产和经营于一体的现代化制药企业。公司荣获1990年度浙江省质量管理奖；2010年获嵊州市市长质量奖；2012年获绍兴市质量进步奖；2012年获绍兴市质量管理星级企业荣誉。2007年“新光”商标被司法认定为“中国驰名商标”。2004年、2008年、2010年、2014年“新光”商标被浙江省工商行政管理局评为“浙江省著名商标”；公司生产的黄芪生脉饮于1990年被评为国家中医药管理局优质产品，1995年被评为首批中国中药名牌产品，2004年、2008年、2010年被评为浙江省名牌产品。
Main Business 中成药、化学药、保健食品的研发、生产和销售
Legal Representative 王岳钧
Top Executives
董事长：王岳钧
董事：马雨阳,邢潇琳,邢宾宾,蒋源洋,裘福寅
独立董事：蔡海静,单伟光,吕圭源
Top 5 Shareholder
Shareholder name Nature Holding Date
王岳钧限售股+流通A股38.25%30/09/2024
嵊州市和丰投资股份有限公司流通A股17.64%30/09/2024
莫常春流通A股1.60%30/09/2024
周慧初流通A股0.43%30/09/2024
夏元丰流通A股0.36%30/09/2024
Company Secretary 蒋源洋
Solicitors 上海市锦天城律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 057583292898
Fax No 057583292898
Website www.xgpharma.com
Email xgpharma@163.com;xgpharma@126.com
Company Address
Register: 浙江省绍兴市嵊州市剡湖街道环城西路25号
Office: 浙江省绍兴市嵊州市剡湖街道环城西路25号
Listing Date 24/06/2016
Shares Capital
Shares Capital: 160,000,000
Total A Share: 160,000,000
Listed A Share: 114,100,000
Non-tradable A Share: 45,900,000
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.400
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 5.276
Market Capitalization(RMB) 1.478B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.